Neuroblastoma Developmental Therapeutics

Ongoing Research

Studies are assessing the safety and efficacy of the ALK inhibitor crizotinib in children with refractory and relapsed neuroblastoma and looking for ways to improve the response to crizotinib.

New drugs are being identified for assessment in clinical trials that target specific genetic profiles in children with neuroblastoma.